IL6 and type 2 diabetes mellitus: In this context, the MiECC could significantly reduce inflammatory cytokines (serum values of IL-1, IL-6, and TNF-α) in non-T2DM and in SGLT2-I users vs non-SGLT2-I users’ patients treated with CABG.